Drug intelligence / Profile preview

TIPRO XP

Development stage: Unknown
Lead developer: Positif Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

TIPRO XP is a nutritional supplement syrup developed and marketed by Positif Life Sciences, an Indian pharmaceutical company. The formulation is a combination of iron choline citrate (15 mg) and the essential amino acid L-lysine (20 mg). Iron choline citrate serves as a source of elemental iron, which is a critical component of hemoglobin and is used to address iron deficiency and prevent anemia. L-lysine is an essential amino acid that supports protein synthesis, tissue repair, and the production of enzymes and hormones, thereby aiding in overall growth and development. The product is positioned within the generic pharmaceutical and nutraceutical portfolio of Positif Life Sciences for nutritional support.

Brand names: TIPRO XP

Beyond the preview

Go deeper on TIPRO XP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TIPRO XP.

Explore the full profile